Phase I Trial of a Single Administration of aKLmRNA-Mediated Protein Replacement Therapy (AKL003)
An Open-Label, Single-Arm Phase I Trial to Evaluate the Safety, Tolerability, and Serum Alpha-Klotho Protein Expression Following a Single Administration of Alpha Klotho mRNA (aKLmRNA), AKL003
This is an open-label, single-arm, single-site Phase I trial in a total of 20 healthy participants at GARM Próspera, Roatán, Honduras. Each participant receives one intravenous administration of 0.5 mg AKL003 on Day 0.
Screening is followed by one treatment visit at GARM Próspera covering Day -1 to Day 2. Scheduled follow-up comprises Day 7 and the actual remote Final Visit (nominal Day 28 ±7 days), following local assessments under Investigator oversight.
Safety is assessed through adverse events, clinical examinations, vital signs, ECG and laboratory testing. Six months of passive safety follow-up after the individual Final Visit or Early Termination Visit.
PsyTool, QoL, Oura and DNA methylation assessments are retained. Exploratory changes do not establish clinical efficacy without a concurrent control group.
研究概览
详细说明
This is an open-label, single-arm, single-site Phase I trial evaluating safety, tolerability and serum alpha-Klotho protein expression after a single intravenous administration of AKL003, a proprietary alpha-Klotho mRNA formulated in lipid nanoparticles. Twenty participants in total will receive AKL003 at GARM Próspera, Roatán, Honduras.
Each participant will receive one 0.5 mg intravenous administration on Day 0. Screening and later laboratory follow-up may be conducted through designated providers in the USA under the responsible Investigator's oversight. One treatment visit at GARM Próspera, Roatán, Honduras is required, covering Day -1 through Day 2. Scheduled follow-up comprises Day 7 and the actual remote Final Visit (nominal Day 28 ±7 days), following local laboratory and physical assessments. All participants follow the protocol-defined eligibility criteria, dose, pre- and post-treatment dexamethasone regimen, assessment schedule and safety procedures.
Systemic reactogenicity events, including fever, headache, myalgia, fatigue, nausea/vomiting, diarrhea and increased heart rate, will be assessed as adverse events. Severity will be graded ; CRS will be graded according to ASTCT criteria where applicable.
All participants will be informed about potential clinical activity and reactogenicity, which may be influenced by increased aKL serum levels or the lipid nanoparticle formulation. Participants will be instructed to contact the trial site to schedule an on-site visit in case of any unexpected adverse event (unscheduled visit,). All such occurrences will be documented as part of the drug candidate's safety evaluation.
Participants will use an electronic diary for daily symptoms through Day 7 and report new or worsening symptoms promptly throughout follow-up. Quality-of-life questionnaires will be completed at baseline and weekly during follow-up, including the actual Final Visit. Oura-derived measures will be collected from screening through the actual Final Visit. PsyTool assessments and other exploratory measures will be collected at different timepoints.
After the individual Final Visit or Early Termination Visit, safety information received during six months of passive follow-up will be assessed. This period adds no scheduled study visits, routine diary entries, questionnaires or biomarker samples. The Investigator may arrange additional care or assessments when clinically indicated.
The primary purpose is safety and tolerability assessment. Without a concurrent control group, exploratory changes may reflect natural variability, practice effects, concomitant factors or expectation effects. They will be interpreted as hypothesis-generating observations.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Agustin Fernandez III
- 电话号码:786-542-5499
- 邮箱:AFS@advantagetherapeutics.com
学习地点
-
-
Bay Islands
-
Roatán、Bay Islands、洪都拉斯、34101
- 招聘中
- GARM
-
接触:
- Heather Terry
- 电话号码:(504) 2408-3544
- 邮箱:heather@garmclinic.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Subjects will only be included in the trial if they meet all following criteria:
- Written informed consent (ICF) signed and dated by the patient
- Ability and willingness to co-operate with the investigator and to comply with the requirements of the entire study.
- Healthy subjects, 35 to 85 years of age
- Sexually active females of childbearing potential and male partners of sexually active females of childbearing potential must use medically accepted form of contraception or be surgically sterile (hysterectomy or bilateral oophorectomy).
- Women of childbearing potential and men with female partners of childbearing potential must use an effective method of birth control during the course of the trial and for at least 90 days after the last dose in a manner such that risk of failure is minimized. Male participants should refrain from donating sperm during the intervention period and for at least 90 days after the last dose of study intervention (see additional considerations in section 5.3)
- Females of childbearing potential must have a negative pregnancy test at the time of enrollment (serum hCG test)
Exclusion Criteria:
Subjects will be excluded from the trial if they present one or more of the following conditions:
- Known of suspected allergy to IMP or related procedure
- Known or suspected allergy, or history of anaphylaxis, to vaccines or their excipients, if considered relevant by the Investigator
- Contraindications for the use of emergency treatments
- Clinically relevant findings at screening, e.g., active diseases of any kind particularly infections
- History of chronic alcohol or drug abuse/ dependence within the past 5 yearsUse of any prescription or over-the-counter medication within 7 days prior to first dosing or planned use during the study period, with the exception of medications considered medically necessary and administered at a stable dose and regimen. Stable medication is defined as medication for which no initiation, discontinuation, or dose adjustment has occurred for at least 3 monthsprior to first dosing and for which no change is anticipated during the study period. Occasional use of paracetamol (acetaminophen) and/or ibuprofen is permitted at the discretion of the investigator.
- Employee at the study site, spouse/partner or relative of any study staff (e.g., investigator, sub investigators, or study nurse) or employee of the Sponsor
- Known or suspected pregnancy, planned pregnancy of lactation
- Clinically significant unstable psychiatric illness in the past 6 months
- Presence of autoimmune disease, autoinflammatory syndrome, or immunological deficiency syndrome (including human immunodeficiency virus (HIV) infection)
- Relevant cardiovascular, hepatic, gastroenterological, respiratory, endocrinological, hematologic disease, or any other condition that, in the Investigator's opinion, could interfere with the analyses of safety and efficacy in this study, unless patient has been on stable doses of medication for any of these concurrent illnesses for at least 3 months prior to study entry
- Presence of end stage kidney failure (on dialysis)
- Current or anticipated use of immunosuppressive drugs such as, but not limited to, azathioprine, cyclosporine, methotrexate, tacrolimus, or mycophenylate within 2 months or any myelosuppressive or cytotoxic chemotherapies within the 12 months prior to the screening visit. Use of systemic corticosteroids equivalent to ≥20mg/week prednisone within the past 4 weeks before screening and during the course of the study (intranasal or inhaled steroids for allergies/asthma is allowed)
- History within the last 2 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate-specific antigen posttreatment; or has a life expectancy of <2 years.
- Patients with long covid-19 showing long-term neurological sequelae within the past 12 months at the time of screening
- Has had a history within the last 5 years of a serious infectious disease affecting the brain, liver, lung and/or kidneys.
- Refractory epilepsy (has had seizures within the past 2 years)
- Hypothyroidism or vitamin B12 deficiency (patients with corrected hypothyroidism or vitamin B12 deficiency are eligible for the study provided that treatment has been stable for 3 months before study entry)
- Patient has hemochromatosis
- 19. Pre-existing anti-PEG antibodies at screening: anti-PEG IgM ≥5,000 U/mL or anti-PEG IgG ≥1,000 U/mL, as measured by the designated screening assay.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:aKLmRNA (AKL003)
Each subject will be treated every 4 weeks for a total of 2 times with aKLmRNA (AKL003) |
Each subject will be treated every 4 weeks for a total of 2 times with aKLmRNA via i.v. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall incidence and severity of unsolicited AEs by treatment group
大体时间:From first dose through end of study (Day 28)
|
• To characterize the overall safety and tolerability of multiple administrations of the Investigational Medicinal product (IMP), aKLmRNA (AKL003), in healthy volunteers |
From first dose through end of study (Day 28)
|
|
• Overall incidence and severity of solicited reactogenicity events by treatment group
大体时间:From first dose through end of study (Day 28)
|
• To characterize the overall safety and tolerability of multiple administrations of the Investigational Medicinal product (IMP), aKLmRNA (AKL003), in healthy volunteers |
From first dose through end of study (Day 28)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
• Increase in serum aKL levels over the mean of the baseline values until end of study
大体时间:Baseline through Day 28
|
• To characterize the serum levels of aKL protein as a function of the dose applied and time post administration. |
Baseline through Day 28
|
|
• aKL serum level by treatment group
大体时间:Baseline through Day 28
|
• To characterize the serum levels of aKL protein as a function of the dose applied and time post administration. |
Baseline through Day 28
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
• Change from baseline to day 60 in episodic memory performance measrued by Face-Name Associative Memory Exam
大体时间:Baseline through Day 28
|
• To characterize the clinical activity after multiple administrations of aKLmRNA AKL003 |
Baseline through Day 28
|
|
• Change from baseline to day 60 in attention and inhibitory control measured Flanker Test
大体时间:Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function |
Baseline through Day 28
|
|
• Change from baseline to day 60 in working memory performance measured by NIH Toolbox List Sorting Working Memory Test
大体时间:Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function |
Baseline through Day 28
|
|
• Change from baseline to day 60 in processing speed assessed by Oral Symbol Digit Test
大体时间:Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function |
Baseline through Day 28
|
|
• Change from baseline to day 60 in reaction time using digital repeated measures
大体时间:Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function, |
Baseline through Day 28
|
|
• Change from baseline in selected standardized neuropsychological assessments aligned with established cognitive testing platforms (CANTAB-based measures)
大体时间:Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function, |
Baseline through Day 28
|
|
• Change from baseline to day 60 in grip strength measured by a hand dynamometer
大体时间:Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, physical (muscle) function |
Baseline through Day 28
|
|
• Change from baseline to day 60 in functional exercise capacity assessed by6 -minute walk test
大体时间:Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, physical (muscle) function |
Baseline through Day 28
|
|
• Change from baseline to day 60 in lower body functional performance assessed by chair-rise or comparable assessment
大体时间:Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, physical (muscle) function |
Baseline through Day 28
|
|
• Change from baseline to day 60 in NAD+ levels measured in serum
大体时间:Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, i immune/inflammatory function |
Baseline through Day 28
|
|
Change from baseline in telomere length (T/S ratio) in peripheral blood mononuclear cells (PBMCs), as measured by quantitative PCR (qPCR), at Day 60
大体时间:Baseline through Day 28
|
Baseline through Day 28
|
合作者和调查者
调查人员
- 首席研究员:Douglas A Tucker, MD、GARM
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.